As previously reported, Leerink analyst Danielle Antalffy upgraded Cardiovascular Systems to Outperform from Market Perform as she believes the company has reached a "fundamental inflection point" given two solid quarters in a row and a new CEO in place. Antalffy says that Cardiovascular Systems' efforts to control cost could push the company to profitability faster than previously expected, turning net income profitable by mid-to-late 2018. Further, the analyst sees the company as poised to turn cash flow positive in the current fiscal year 2017. Antalffy raised her price target on the shares to $30 from $23.